Business
MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue
FY 2025 revenue of $45.1 million, an increase of 8% over 2024 International Medical Cannabi...
About this update from Medipharm Labs Corp.
[{"type":"text","content":"MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue\nFY 2025 revenue of $45.1 million, an increase of 8% over 2024International Medical Cannabis revenue increased 43% year-over-year and represented more than 50% of total revenueIncreased cash balance of $10.8 Million at the end of Q4, up $0.2 million from Q3 2025Company remains virtually debt-free, with outright ownership of two production facilitiesManagement to Host Conference Call / Webcast on March 30th, 2026, at 10:00 am ET TORONTO, March 30, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (\"MediPharm\", \"MediPharm Labs\" or the \"Company\"), a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the full year and three months ended December 31, 2025. MediPharm achieved 8% annual revenue growth in 2025, driven by the continued execution of its international medical cannabis strategy. International medical cannabis revenue contributed more than 50% of total revenue, reflecting strong global demand for MediPharm products. The Company maintained a measured approach to cost controls, and monetized non-core assets to further strengthen its balance sheet and capital position versus many industry peers. These results reflect MediPharm’s commitment to responsible growth, financial discipline, commercial acumen and long-term value creation.    “We ended 2025 stronger, with 8% revenue growth supported by 43% year over year growth in our international medical cannabis business and a robust platform designed for regulated markets,” said Greg Hunter, CFO and Interim CEO of MediPharm Labs. “As a result of our efforts, we exited 2025 with a more resilient and diversified revenue mix and strong balance sheet with virtually no debt and over $10 million in cash. Looking ahead, we are planning for continued expansion of both our product portfolio and geographic reach, including advancing opportunities in markets such as Brazil, France, and New Zealand, while maintaining a disciplined approach to growth.” Commercial Highlights & Revenue Performance 2025 revenue was $45.1 million, representing 8% year over year growth, driven by International Medical Ca...